Mr. El-Hibri is the Chairman of Aptevo Therapeutics’ Board of Directors. Mr. El-Hibri is the founder and Executive Chairman of the Board of Directors of Emergent BioSolutions. Mr. El-Hibri has served as the executive chairman of Emergent’s Board of Directors since April 2012. From June 2004 to March 2012, Mr. El-Hibri served as Chief Executive Officer and Chairman of Emergent’s Board of Directors. Mr. El-Hibri previously served as President of Emergent from March 2006 to April 2007. Mr. El-Hibri served as Chief Executive Officer and Chairman of the Board of Directors of BioPort Corporation, or BioPort, from May 1998 until June 2004, when, as a result of Emergent’s corporate reorganization, BioPort became a wholly-owned subsidiary of Emergent and was subsequently renamed Emergent BioDefense Operations Lansing Inc. Mr. El-Hibri is Chairman of East West Resources Corporation, a venture capital and business consulting firm, a position he has held since June 1990. He served as President of East West Resources from September 1990 to January 2004.
Mr. White leads Aptevo Therapeutics as the President and Chief Executive Officer. Prior to this role he was a member of Emergent BioSolutions’ Board of Directors. He is the former Chief Financial Officer of St. Vincent’s Health, a $2.8 billion multi-hospital health system. Mr. White previously served as Executive Director and CFO of Lilly USA, a subsidiary of Eli Lilly and Company, and held other positions in corporate finance at Eli Lilly and Company. He currently serves on the board of OneAmerica Financial Insurance Partners, Inc., and was previously on the board of Washington Prime Group and CoLucid Pharmaceuticals, Inc.
Daniel J. Abdun-Nabi
Mr. Abdun-Nabi served as the President and Chief Executive Officer of Emergent BioSolutions from April 2010 until his retirement from Emergent in April 2019. From May 2007 to March 2012, Mr. Abdun-Nabi served as Emergent’s President and Chief Operating Officer. Mr. Abdun-Nabi previously served as Emergent’s Corporate Secretary from December 2004 to January 2008, Emergent’s Senior Vice President, Corporate Affairs and General Counsel from December 2004 to April 2007 and Emergent’s Vice President and General Counsel from May 2004 to December 2004. Mr. Abdun-Nabi served as General Counsel for IGEN International, Inc., a biotechnology company, and its successor BioVeris Corporation, from September 1999 to May 2004. Prior to joining IGEN, Mr. Abdun-Nabi served as Senior Vice President, Legal Affairs, General Counsel and Secretary of North American Vaccine, Inc., a private vaccine company acquired by Baxter International Inc. in 2000. Mr. Abdun-Nabi is currently a member of the board of RegenxBio.
Grady Grant, III
Mr. Grant is currently the Vice President of Sales for Tissue Tech Limited. From December 2011 to August 2018, he worked as Vice President of Medical Sales for Mead Johnson Nutrition, a public company focused on pediatric nutrition. He has held this position since December 2011, preceded by 30 years of service at Eli Lilly and Company which includes his service as Vice President of Sales Neuroscience from January 2006 to December 2011.
Zsolt Harsanyi, Ph.D.
Dr. Harsanyi serves on the Board of Directors of Emergent BioSolutions. Dr. Harsanyi has served as Chairman of the Board of N-Gene Research Laboratories, Inc., a privately-held biotechnology company, since March 2011. Prior to that, Dr. Harsanyi served as Chief Executive Officer and Chairman of the Board of Directors of Exponential Biotherapies Inc., a private biotechnology company, from December 2004 to February 2011. Dr. Harsanyi served as President of Porton International plc, or Porton International, a pharmaceutical and vaccine company, from January 1983 to December 2004. Dr. Harsanyi was a founder of Dynport Vaccine Company LLC in September 1996. Prior to joining Porton International, Dr. Harsanyi was Vice President of Corporate Finance at E.F. Hutton, Inc. Previously, Dr. Harsanyi directed the first assessment of biotechnology for the U.S. Congress’ Office of Technology Assessment, served as a consultant to the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research and was on the faculties of Microbiology and Genetics at Cornell University Medical College.
Barbara Lopez Kunz
Ms. Kunz is currently the Global Chief Executive of the Drug Information Association, a private health care products company. From January 2007 to March 2013, she worked as President of Health and Life Sciences at Battelle Memorial Institute, a private nonprofit applied science and technology development company. From August 2003 to December 2007, she worked as Senior VP/GM for Thermo Fisher Scientific’s Fisher Biosciences and led the Latin America regional business from January 2000 to July 2003 at Uniqema, a private company acquired by Croda International plc in 2006.
John E. Niederhuber, M.D.
Dr. Niederhuber is the founder, Executive Vice President, and Chief Executive Officer of the Inova Translational Medicine Institute, a not-for-profit genomics research institute. Dr. Niederhuber served as a director of Emergent from August 2010, until his resignation from the Emergent Board of Directors in May 2016. He previously served as the Director of the National Cancer Institute (NCI), the National Institutes of Health from 2006 to 2010. Dr. Niederhuber joined the Inova Health System in August 2010 as Executive Vice President and CEO of the Inova Translational Medicine Institute. Dr. Niederhuber is also an adjunct professor of surgery and oncology at the Johns Hopkins University School of Medicine. Prior to joining NCI, Dr. Niederhuber was Director of the University of Wisconsin Comprehensive Cancer Center and professor of surgery and oncology (member of the McArdle Laboratory) at the University of Wisconsin School of Medicine from 1997 to 2005. He chaired the Department of Surgery at Stanford University School of Medicine from 1991 to 1997 and held professorships at the Johns Hopkins University School of Medicine from 1987 to 1991 and at the University of Michigan from 1973 to 1987.